Altus kept at buy by Merrill

Altus Pharmaceuticals Inc: was maintained at a buy rating by Merrill Lynch analyst Tom McGahren on news that the Food and Drug Administration published a revised industry guidance for manufacturers of pancreatic enzyme products (PEPs), which could make it easier for current PEP manufacturers to secure FDA approval by the agency's April 2008 deadline. Even so, since ALTU-135 is a recombinantly derived (no pigs) PEP, it offers advantages in terms of consistency, safety and lower pill burden. Shares of the Cambridge, Mass., biopharmaceutical company were down 34 cents, or 1.59%, at $20.99 on volume of 185,414 shares versus the three-month running average of 204,421 shares. (Nasdaq: ALTU)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.